teclistamab
genmab,janssen
['majestec-1', 'teclistamab', 'mmsm']
update on majestec-1 study of teclistamab, a bcma/cd3 bispecific antibody. overall response of 63%, with a possible signal of even better efficacy in patients with less that 3 prior lines of therapy. development is ongoing. #mmsm #asco2022 
Multiple Myeloma Research Foundation - Accelerating the development of next generation #myeloma treatments to extend patient’s lives, and lead to a cure.